Gender differences in XXXX and @entity174 .

@entity1 @entity170 @entity174
BACKGROUND: @entity170 is generally thought of as a " @entity1 's disease" because the prevalence of @entity170 and the rate of @entity174 are much higher in postmenopausal @entity1 than in older @entity1 . However, the absolute number of @entity1 affected by @entity170 and @entity174 is large, as at least 2.8 million @entity1 in the United States are thought to have @entity170 . QUESTIONS/PURPOSES: The purposes of this review are to (1) highlight gender differences in @entity170 and @entity174 risk, (2) describe disparities in treatment and outcomes after @entity174 between @entity1 and @entity1 , and (3) propose solutions to reducing disparities in treatment and prevention. METHODS: A literature survey was conducted using MEDLINE with a variety of search terms and using references from the author's personal collection of articles. A formal search strategy and exclusion criteria were not employed and the review is therefore selective. WHERE ARE WE NOW?: Postmenopausal @entity1 have a higher prevalence of @entity170 and greater incidence of @entity174 than older @entity1 . Despite the higher @entity174 risk in postmenopausal @entity1 , older @entity1 tend to have worse outcomes after @entity174 and poorer treatment rates, although less is known about the disease course in @entity1 . Multifaceted interventions to improve the screening and treatment for @entity170 were recently developed. WHERE DO WE NEED TO GO?: Improvement in treatment rates of those at risk, regardless of gender, is an important goal in @entity170 management. HOW DO WE GET THERE?: Further development and evaluation of cost-effective, multifaceted interventions for screening and treatment of @entity170 and @entity174 are needed; such interventions will likely improve the primary prevention of @entity174 .
